UPCOMING SESSIONS in ET
Wed, Apr 1, 2026
10:00 – 11:00 PM UTC
Facing Fear & Pain in Amyloidosis: How to Take Back Control and Shorten the Storm Cath Jayasuriya Click To Register
UPCOMING SESSIONS in ET
Wed, Apr 1, 2026 · 10:00 – 11:00 PM UTC
Facing Fear & Pain in Amyloidosis: How to Take Back Control and Shorten the Storm
Cath Jayasuriya
Click To Register
View all sessions

Bortezomib

Jun 03, 2018
Subcutaneous Daratumumab (DARA SC) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Patients (Pts) With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of Andromeda
Background: Systemic AL amyloidosis is characterized by disposition of insoluble amyloid fibrils into tissues and organs via clonal expansion of CD38+ plasma cells…
Read more
Mar 06, 2018
The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis
Bortezomib began to be used in the treatment of light chain (AL) amyloidosis in recent years. We performed the first meta-analysis of randomized clinical trials and…
Read more
Subscribe to